Human inborn errors of immunity: An expanding universe

Luigi D. Notarangelo1*,†, Rosa Bacchetta2*, Jean-Laurent Casanova3,4,5,6,7*, Helen C. Su1*

Molecular, cellular, and clinical studies of human inborn errors of immunity have revolutionized our understanding of their pathogenesis, considerably broadened their spectrum of immunological and clinical phenotypes, and enabled successful targeted therapeutic interventions. These studies have also been of great scientific merit, challenging a number of immunological notions initially established in inbred mice while revealing previously unrecognized mechanisms of host defense by leukocytes and other cells and of both innate and adaptive tolerance to self.

INTRODUCTION

Primary immune deficiencies (PIDs) have been classically characterized by increased susceptibility to infections due to genetic defects affecting the development and/or function of the immune system. The history of PIDs is typically dated back to 1952, when Bruton (1) described a boy who had suffered from 19 episodes of pneumococcal infections, lacked serum γ-globulins, and recovered upon intramuscular administration of γ-globulins. Two years earlier, Glanzmann and Riniker (2) had described an infant with severe lymphopenia and atrophy of lymphoid tissues who succumbed to infections early in life. Subsequently, Hitzig et al. (3) reported other infants with early-onset life-threatening infections who lacked both γ-globulins and lymphocytes. This condition, which was initially named Swiss-type agammaglobulinemia (4) (to distinguish it from Bruton's agammaglobulinemia), is now referred to as severe combined immune deficiency (SCID). Together, isolated agammaglobulinemia and SCID provided evidence of the critical role played by humoral and cellular immunity, respectively, in protection against infections, paving the way to the discovery of T and B cells few years later (5).

The first inborn errors of innate immunity defects were also reported in the 1950s. In 1950, Kostmann (6) described the first patient with severe congenital neutropenia. While searching for other cases of hypogammaglobulinemia, Janeway et al. (7) reported in 1954 a patient with recurrent infections and, paradoxically, elevated serum immunoglobulins. The patient was found in 1957 to suffer from a congenital defect of phagocyte function, designated as chronic granulomatous disease in 1957 (8). Inborn errors of complement were described from the 1960s onward. It was soon recognized that the nature of pathogens (viruses, bacteria, fungi, or parasites, “opportunistic” or not) causing infections in patients with PID is largely determined by the arm of immunity that is affected (T lymphocytes, B lymphocytes, phagocytes, and complement). PIDs in any category have long been defined by susceptibility to a broad range of pathogens. Although clinically and immunologically homogeneous forms of PIDs [agammaglobulinemia, SCID, and chronic granulomatous disease (CGD)] were evidently transmitted with different patterns [X-linked and autosomal recessive (AR)], too few immunological reagents were then available to distinguish different forms of PID in each category. Consequently, only a handful of distinct disorders were included in the first classification of PIDs in 1968, which, incidentally, did not include neutropenia, because it was regarded by immunologists of the time as a hematological condition (9).

Over the years, it has been recognized that depending on the specific nature of the disease, autoimmunity, autoinflammation, allergy, and malignancy can be common, and in some cases, predominant clinical manifestations associated with monogenic defects of immunity (10). To capture this broad range of phenotypes associated with these disorders, the term “inborn errors of immunity” (IEI) has been proposed. Importantly, advances in molecular genetics and cellular immunology have allowed a much more precise definition of various forms of IEI (Fig. 1). Use of next-generation sequencing has permitted the identification of a growing number of IEI (Fig. 2A), whose number has now reached 431 in the 2020 classification from the International Union of Immunological Societies Committee on Inborn Errors of Immunity (11). At the molecular level, it has been shown that most IEI can be caused by mutations in different genes (locus heterogeneity), which typically govern a certain pathway. More surprisingly, distinct pathogenic variants at the same locus have also been shown to cause different forms of IEI, usually but not necessarily because of different genotypes [allelic heterogeneity; monoallelic versus biallelic lesions, loss-of-function (LOF) (or hypomorphic) versus gain-of-function (GOF) (or hypermorphic) variations, and dominant-negative versus haploinsufficient mode of dominance].

Following up on the surprising observation that patients with AR defects in the terminal components of complement were selectively prone to Neisseria infections, it was gradually realized that many other IEI manifest as susceptibility to a narrow group of pathogens (12). Furthermore, some of these IEI have been shown to reflect genetic defects that are extrinsic to the hematopoietic system, reflecting instead functional abnormalities of cell types other than leukocytes (13).

Importantly, it has also been recognized that depending on the specific IEI, autoimmunity, autoinflammation, allergy, and malignancy can be common, and in some cases, predominant clinical manifestations (10). Last, the in-depth characterization of the molecular, cellular, and immunological mechanisms of disease has permitted a shift from supportive (mostly focusing on prevention and
The spectrum of IEI: Phenotypes and genotypes

Combined immunodeficiencies: Uncovering pathways to T cell development and immune regulation

Following the first descriptions of SCID in the 1950s, a growing number of patients with early-onset life-threatening infections and lymphopenia were described in the next decades. A first evidence of genetic heterogeneity came with the observation that SCID was inherited as an X-recessive (XR) (17) or AR trait (3). After T and B lymphocytes [and later on, natural killer (NK) cells] were described, it was further found that SCID comprises different conditions, all of which are characterized by lack of autologous T cells, whereas B and/or NK cells may either be present or absent.

Eventually, cloning of SCID-causing genes revealed an even higher level of heterogeneity. The first SCID disorders that were defined at the molecular level were adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) deficiency. The metabolic basis of these disorders was established by Eloise Gibblett in 1972 and in 1975, respectively (18, 19), whereas ADA and PNP mutations were reported in 1985 and 1987. Along with mutations in CYBB, causing X-linked granulomatous disease (20), mutations underlying ADA deficiency were actually the first identified in the entire field of IEI.

The molecular pathogenesis of XR-SCID was revealed in 1993, with mutations in the IL2RG gene (21). This gene was initially thought to code only for the γ chain of the interleukin-2 (IL-2) receptor; however, it was soon found that the γ chain is also a subunit of receptors for IL-4, IL-7, IL-9, IL-15, and IL-21 and for this reason is also referred to as the common γ chain (γc) and that it is constitutively associated with the intracellular tyrosine kinase Janus kinase 3 (JAK3) (22). These observations led to the identification of JAK3 deficiency as an AR form of SCID, which is clinically and immunologically indistinguishable from XR-SCID (23). Important differences emerged when comparing the immunological phenotype of patients and mice with genetic defects of γc signaling. In particular, γc and JAK3 defects in mice are associated with a T− B− NK− SCID phenotype, whereas in humans they cause T− B− NK− SCID. The discovery of patients with AR IL-7R deficiency as an etiology of T− B− NK− SCID revealed that abolished IL-7 signaling plays a critical role in the SCID phenotype of IL2RG- and JAK3-deficient patients, whereas it has no impact on B cell development in humans, unlike in mice (24). The more recent discovery that patients with AR IL-7 deficiency display a milder T cell deficiency suggests that abrogated responses to thymic stromal-derived lymphopoietin (TSLP), which also engages the IL-7R, contributes to the SCID phenotype of AR IL-7R deficiency (25, 26).

Many other gene defects accounting for defects of T cell development were identified from the late 1990s onward. In some cases, these studies revealed previously unappreciated molecules and mechanisms that govern T cell development, preceding the generation of animal mutants. This was the case for ARTEMIS and Cernunnos/XLF defects that compromise V(D)J recombination and DNA repair (27–29), for AK2 deficiency that compromises mitochondrial function and cell survival in reticular dysgenesis (30, 31), as well as for various defects of transcription factors that account for human leukocyte antigen (HLA) class II deficiency (32–35). In other cases, mutations were found in human orthologs of genes previously studied in mice, such as RAG1 (36) and RAG2 (37).

Advances in molecular genetics have enabled the identification of a growing number of genetic etiologies of combined immune deficiency (CID). At variance with SCID, CID disorders are characterized by a less severe numerical and/or functional T cell defect. Furthermore, whereas early-onset, life-threatening infections are the hallmark of SCID, various forms of immune dysregulation (such as autoimmune

Fig. 1. Evolution of clinical, pathophysiological, diagnostic, and therapeutic approach to inborn errors of immunity.
Defects of SCID or CID (Fig. 2B). Mutations in the same gene can underlie variable numbers of T and B cells. Patients with LOF RAG1 or RAG2 mutations display a T” B NK” SCID phenotype, whereas severely hypomorphic mutations often underlie Omenn syndrome, in which oligoclonal T cells infiltrate the skin and other target tissues. By contrast, less severely hypomorphic RAG gene variants are typically associated with autoimmunity and granulomatous lesions (42). The immune dysregulation of RAG deficiency (and of other forms of CID) reflects perturbations in the mechanisms of negative selection of self-reactive T and B lymphocytes and poor function [or restricted T cell receptor (TCR) repertoire] of regulatory T cells (Treg) (41).

Major progress has been made in the screening of inherited T cell disorders. Measurement of TCR excision circles, a by-product of V(D)J recombination at the TCRα/β locus (43), in dried blood spots collected at birth can identify newborns with severe T cell lymphopenia (TCL). Immunological and genetic studies are needed to diagnose SCID as opposed to other causes of TCL, such as prematurity, some syndromic conditions, chylothorax and other causes of T cell loss, and use of some immunosuppressive drugs during pregnancy (44). The implementation of universal newborn screening (NBS) for SCID in the United States has revealed an incidence of SCID of about 1:65,000, which is substantially higher than previously thought (44). By allowing early identification of SCID babies, NBS facilitates interventions aimed at preventing infections and rapid referral to HSCT. This is especially important because it has been shown that younger age and infection status at transplantation are key factors that determine improved outcome after HSCT for SCID (45, 46).

**Monogenic errors of immune regulation**

The understanding of immunological self-tolerance and autoimmunity greatly benefited from studies of monogenic inborn errors of T cell tolerance, T cell apoptosis, or Treg, each presenting with distinctive immunological and clinical manifestations but unified by pathological self-reactive T cell responses.

One of the longest-studied examples of such disorders, first reported by Leonard in 1929, as an AR condition known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome [APECED; also known as type 1 autoimmune polyglandular syndrome, (APS1)] [reviewed in (47)]. From a clinical standpoint, APECED is characterized by pleiotropic autoimmune manifestations and the presence of tissue- and cytokine-specific autoantibodies. The disease is caused by mutations in AIRE, a key transcription factor that regulates tissue-restricted self-antigen expression in medullary thymic epithelial cells, thereby governing negative selection of autoreactive T cells (48). In patients with APECED, thymic escape of self-reactive TCRβ” CD4” T cells causes autoimmunity. Furthermore, an altered positive selection of thymic Treg, increased autoreactive B cells, and production of autoantibodies further aggravate the autoimmunity of the disease (49–51). Adoptive transfer experiments in mouse models of APECED support a predominant pathogenetic role of self-reactive T cells, whereas autoantibody formation appears largely secondary to, rather than causative of, tissue damage (52).

Patients with APECED typically suffer from hypoparathyroidism, adrenal insufficiency (Addison’s disease), and chronic mucocutaneous candidiasis (CMC). Other autoimmune endocrine problems (hypothyroidism and ovarian and testicular failure hypopituitarism), skin lesions (urticarial eruption, alopecia, and vitiligo), and pulmonary, gastrointestinal, liver, renal, and ocular manifestations are frequently seen (47). Neutralizing anti–IL-17A/F antibodies are often present in patients with APECED and play a pathogenic role in CMC (53, 54). This is an example of increased susceptibility to infection due to an autoimmune mechanism. In addition to anti–IL-17A/F autoantibodies, patients with APECED have anti–interferon-α (IFN-α) and anti–IFN-ω autoantibodies, which are not known to be pathogenic but represent useful diagnostic biomarkers. Because the defect is in the thymic epithelial cells and not in hematopoietic cells, there are currently no curative approaches for APECED, and patients with this disease have an increased mortality rate and a poor quality of life.

Autoimmune lymphoproliferative disease (ALPS) is another form of monogenic autoimmunity, which is caused by germline or somatic mutations in TNFRSF6, TNFSF6, and CASP10, coding for FAS/CD95, FAS ligand (Fasl), and caspase-10, respectively. These defects impair FAS/CD95-mediated cell death of lymphocytes, leading to the main clinical manifestations of lymphadenopathy, splenomegaly, and autoimmune cytopenias [reviewed in (55, 56)]. An unusual population of TCRβ” CD4” CD8” double-negative T (DNT) cells...
infiltrates and accumulates within lymphoid organs. These DNT cells resemble CD45⁺ effector memory T (TEMRA) cells, because they express not only the naïve marker CD45RA but also activation and exhaustion markers. In some patients, DNT cells are the only cell type carrying the mutation, supporting their important pathogenic role. B cells are also altered in ALPS, with decreased marginal zone and memory B cells, abundant plasma cells, and increased levels of immunoglobulin G (IgG) and IgA. Other diagnostic biomarkers include elevated serum levels of IL-10, soluble FasL, and vitamin B12. Although lymphoproliferation tends to improve in adulthood, patients with ALPS usually require immunosuppression and have an increased risk of lymphoma. Related disorders of defective apoptosis are caused by caspase-8 (57), FADD (Fas-associated death domain) deficiencies (56), or activating mutations in NRAS (58, 59), which are associated with other immunological and clinical phenotypes.

A third form of monogenic autoimmune disorders is inborn errors of Treg function, collectively called Tregopathies [reviewed in (60)]. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome [reviewed in (61)], affecting CD4⁺CD25⁺CD127⁻ thymic-derived Treg, represents the prototype of this group of disorders. IPEX was first clinically described in 1982 by Powell et al. (62), and its successful treatment with HSCT (proving the hematopoietic intrinsic nature of the disease) was reported in 2001 (63). Around the same time, three groups described mutations in human FOXP3 (64–66). In 2003, several publications connected Foxp3 mutations, defective Treg, and autoimmunity in mice (67–69). Defective Treg function in patients with IPEX [with impaired capacity to suppress proliferation and cytokine production of T effector (Teff) cells] was reported in 2006 (70), establishing Treg dysfunction as the primary pathogenic cause of IPEX. FOXP3-mutated effector T cells have an increased proliferative capacity, and their cytokine expression profile is skewed toward T helper 2 (Th2) and Th17 cells, which may contribute to the autoimmune pathology and probably to atopic disease as well (61, 71).

In most patients with IPEX, the disease manifests within the first months of life (72), with severe enteropathy, type 1 diabetes, and skin disease resembling atopic dermatitis. Cytopenias and autoimmune hepatitis are also very common. In some cases, however, FOXP3 mutations are detected in adolescents with milder or atypical autoimmune manifestations, including thyroiditis, glomerulonephritis, alopecia, psoriasis, or arthritis. An increased CD4⁺CD8⁺ ratio, eosinophilia, and elevated serum IgE are typical biomarkers of the disease. Tissue-specific autoantibodies are frequently detected; in particular, antiharmonin and antivillin antibodies are associated with enteropathy (73). The enumeration of circulating Treg cells and the evaluation of FOXP3 expression have limited diagnostic value, because some patients express fairly normal amounts of mutated FOXP3 protein. DNA demethylation at the Treg-specific region (TSDR) of the FOXP3 gene promoter is a requirement for stable FOXP3 expression (74). Increased TSDR demethylation (suggesting a possible compensatory mechanism) has been reported in patients with IPEX and may represent an important diagnostic aid (75). IPEX is a life-threatening disease, with limited response to immunosuppression and poor long-term disease-free survival. HSCT can be curative, although the clinical status of the patients at the time of transplant can negatively affect the outcome (72).

IPEX-like diseases are caused by mutations in genes encoding molecules involved in survival, development, signaling, or function only not of Treg, but also of Teff cells (60, 76). This group of disorders comprises defects in several genes: (i) CD25, encoding the α chain of the IL-2 receptor (IL-2Rα) complex, which is essential for Treg peripheral survival and Teff expansion and for sustaining antigen-specific T cell immune responses. CD25 deficiency manifests with enteropathy, other autoimmune features, and increased susceptibility to infections, in particular to cytomegalovirus. In a few cases, all carrying the same mutation, autoimmunity has been reported as the only clinical feature (77). Biallelic mutations in CD122, encoding for IL-2Rβ, cause similar clinical manifestations (78, 79), and mutations in STAT5B, which lead to growth hormone insensitivity and short stature, also impair IL-2 signaling and Treg fitness (80, 81). (ii) CTLA4, encoding a negative regulator of T cell responses. The CTLA-4 protein is constitutively expressed by Treg and directly regulated by FOXP3, in contrast to its inducible expression in Teff cells. By competing with CD28 for binding to the costimulatory molecules CD80 and CD86, expressed on the surface of antigen-presenting cells, CTLA-4 blocks T cell activation. CTLA4 haploinsufficiency is characterized by lymphoproliferation [including lymphoid infiltrates in the lungs and in the central nervous system (CNS)], increased susceptibility to infections, and autoimmunity (enteropathy, cytopenias, and skin lesions) (82, 83). The disease has incomplete penetration. (iii) LRBA, encoding an anchor protein involved in membrane recycling of CTLA-4 (84). LRBA deficiency is an AR disease with similar manifestations to CTLA-4 haploinsufficiency but with earlier clinical onset and complete penetrance (85). Recently, mutations in DEF6, also involved in CTLA-4 membrane trafficking, have been described (86). (iv) STAT3, encoding a signaling mediator of many cytokine receptors. GOF STAT3 mutations are associated with reduced signal transducer and activator of transcription 5B (STAT5B) signaling and impaired FOXP3 and IL17A expression. The clinical manifestations are heterogeneous, including autoimmune polyendocrinopathy, cytopenias, enteropathy, and lung disease, as well as recurrent infections and short stature (87). Related to altered STAT3 signaling are also IL10, IL10RA, and IL10RB mutations, which affect the production of, and response to, the immunosuppressive cytokine IL-10. IL-10 antagonizes IFN-γ and is also important for gut immune homeostasis and for the induction of type 1 Treg (88). Loss of IL-10 or IL-10 responsiveness causes a disease that manifests primarily with very-early-onset inflammatory bowel disease (89, 90). Together, this third group of Tregopathies illustrates the many pathways regulating this cell subset that is important for maintaining immune homeostasis and preventing autoimmunity.

Autoinflammatory disorders: IL-1 and type I IFN-associated diseases

Autoinflammatory diseases are defined by fever, skin rashes, or other manifestations of inflammation, in the absence of autoimmunity and infection or disproportionate to a precipitating infection [reviewed in (91)]. Two major groups of monogenic autoinflammatory disorders are the IL-1 inflammasomopathies and the type I interferonopathies. In inflammasomopathies, overactivation of IL-1β and related cytokines like IL-18 results from dysregulated inflammasome activation. Normally, various stimuli that cells interpret as danger or damage, including microbial products or microcrystals, trigger the assembly of inflammasomes in the cytosol. The inflammasome is a multimeric signaling complex that brings together through homotypic interactions NLRP1, NLRP3, or NLRC4 sensor proteins with pyrin and ASC. Entry of procaspase-1 into this complex promotes self-cleavage for activation. The activated caspase-1, in turn, cleaves to activate the proinflammatory cytokines IL-1β and IL-18, which unleash a cascade of diverse biological effects including leukocyte...
extravasation into tissues, modulation of immune cell functions, and induction of fever, acute phase reactants, and other metabolic changes. In addition, activated caspase-1 cleaves and activates gasdermin D, which forms pores in the membrane to cause pyroptotic cell death.

Monogenic autoinflammatory disorders caused by dysregulated inflammasome activation and/or hyperactivation of the IL-1 pathway are exemplified by familial Mediterranean fever due to mutations in MEFV encoding pyrin. However, inflammasomopathies have since broadened to include those stemming from GOF mutations in other inflammasome components (NLRP3, NLRC4, and NLRP1) or in molecules upstream that regulate inflammasome activation (LPIN2, PSTPIP1, MKV, and WDR1). In addition, inflammasomopathies include LOF mutations that decrease IL-1 antagonism (IL1RN). In contrast, genetic loss of human IL-18 antagonist (mutations in IL18BBP) does not underlie autoinflammation but excessive inflammation and liver destruction in response to hepatitis virus A infection (92). As would be expected from their shared pathogenic mechanism, most inflammasomopathies are amenable to primary or adjunctive treatments targeting production of or responsiveness to IL-1 (91).

By contrast, interferonopathies, which constitute a second group of monogenic autoinflammatory disorders, are caused by overactivation of type I IFNs and IFN-stimulated genes (ISGs) or IFN-regulated genes (IRGs) (93). Normally, the accumulation of virus products—such as nucleic acid structures not normally found in uninfected cells or found in inappropriate cellular compartments—are detected by various intracellular sensors. These sensors encompass RIG-I, certain Toll-like receptors (TLRs), and cyclic guanosine monophosphate–adenosine monophosphate synthase. Their binding to virus products triggers the assembly of signaling platforms that turn on the transcription of antiviral type I IFNs and proinflammatory cytokines. Interferonopathies can result from GOF mutations in the virus sensors or associated adaptors (IFIH1, DDX58, and TMEM173) or LOF mutations in nucleases or in RNA-editing enzymes (TREX1, SAMHD1, ADAR1, RNASEH2A, RNASEH2B, and RNASEH2C) that lead to abnormal accumulation of endogenous nucleic acids. Alternatively, LOF mutations that negatively regulate the IFN responsive pathway (“the” hyper-IgE syndrome (HIES) whose clinical and immunological features were described between 1966 and 1999 (99, 100). These patients suffer from severe eczema and show elevated serum IgE levels, which can show reactivity toward a variety of allergens. The patients also suffer from severe infections, especially CMC and staphylococcal diseases of the skin and lungs, often with pustulomasles that are prone to superinfection. Another characteristic feature of HIES is the poor clinical and biological inflammation, with cold abscesses of the skin and lungs. A fourth defining phenotype includes a range of extrahematopoietic manifestations, including skeletal disorders in particular, such as bone fragility, scoliosis, and decidual teeth retention. Two of these four cardinal features can be seen in similar but unrelated disorders: Eczema, infection susceptibility, and elevated IgE are seen for example in patients with deductor of cytokinesis 8 (DOCK8) deficiency, whereas poor inflammation in the course of skin or systemic, but rarely pulmonary, staphylococcal infection is seen in patients with MyD88 or IL-1 receptor–associated kinase 4 deficiency. It is the combination of these four phenotypes that makes the HIES a distinctive clinical entity. This by no means implies that all patients are closely similar. There is actually great interindividual variability among patients with HIES, even within a given family.

The first step toward the molecular and cellular dissection of the HIES came in 2007 with the discovery of heterozygous HIES-causing mutations in STAT3 (101). The mutations are LOF and dominant negative. Even low amounts of STAT3 can exert negative dominance. An AR form of HIES was found in 2018 with biallelic mutations in ZNF341, a transcription factor that governs the baseline and inducible transcription of STAT3, thereby also regulating its expression
and activity (102, 103). Severely hypomorphic mutations of the *IL6ST* gene were reported to underlie a severe AR form of HIES (104). The *IL6ST* gene encodes for the gp130 co-receptor of IL-6 family cytokines, including IL-6, IL-11, IL-27, oncostatin M, and leukemia inhibitory factor; all of these receptors signal via STAT3. A complete form of gp130 deficiency underlies an even more severe condition, evoking Stieve-Wiedemann syndrome (105). A second genetic etiology of autosomal dominant HIES is due to heterozygous, dominant-negative mutations in *IL6ST*, which impair cellular responses to IL-6 and IL-11 to a greater extent than other IL-6 family cytokines (106).

The immunological and clinical phenotypes of the patients with these three genetic etiologies of HIES largely, but not completely, overlap, possibly reflecting differences in the biochemical pathways affected. Cells from patients with HIES mutated in *STAT3*, *ZNF341*, or *IL6ST* respond poorly to IL-6 family cytokines. Cells mutated in *STAT3* or *ZNF341* also respond poorly to IL-21 and IL-23. The discovery of other IEI has shed light onto the molecular and cellular basis of each of the cardinal HIES phenotypes. Their staphylococcal disease results mostly from impaired responses to IL-6, as inferred from the discovery of patients with AR IL-6R deficiency (107). Interestingly, their eczema and elevated IgE levels, as well as their poor inflammation, also seem to result mostly from insufficient responses to IL-6. In contrast, IL-6R–deficient patients do not display skeletal phenotypes. The skeletal manifestations seen in patients with HIES result, at least in part, from the poor cellular responses to IL-11, as inferred from the discovery of patients with IL-11R deficiency and Crouzon-like skeletal anomalies (108). Some other shared features of HIES remain unexplained in molecular terms, e.g., vascular anomalies and lymphomas.

Although the four genetic etiologies of HIES seem to be broadly responsible for phenocopies, a detailed and systematic clinical survey would be useful. Anecdotally, it seems that ZNF341–deficient patients have a better inflammatory response and fewer somatic manifestations than *STAT3*-mutated patients, but the underlying mechanisms for this remain unknown. Moreover, *STAT3*– and *ZNF341*–mutated patients frequently have CMC, unlike *IL6ST*– and *IL6ST*–mutated patients. The former patients display CMC because of impaired development of Th17 and perhaps other IL-17–producing lymphocytes, as inferred from inborn errors of IL-17. Although isolated defects of IL-6R, IL-21R, and IL-23R do not or rarely underlie CMC (109, 110), their combined deficiency via mutations in *STAT3* or *ZNF341*, but not *IL6ST*, commonly underlies CMC. Overall, core molecular deficiencies of these three groups of patients with HIES involve an impaired ZNF341– and STAT3–dependent IL-6 signal transducer (IL-6ST)–mediated response to IL-6 (allergy and staphylococcal disease) and IL-11 (skeletal anomalies), whereas at least some specific features, such as CMC, are caused by ZNF341– and STAT3–dependent impairment of IL-17.

**IEI with increased susceptibility to Epstein-Barr virus infection and malignancies**

Some IEIs result from genomic instability, apoptosis defects, and other abnormalities that predispose to cancer, without necessarily interfering with immune responses (111). However, other PID have an increased risk of cancers due to inadequate control by the immune system of oncogenic viruses such as human papillomaviruses (HPVs), human herpes virus 8, and Epstein-Barr virus (EBV). Of these, EBV is illustrative because it infects nearly all adults [reviewed in (112)]. Patients with PID can develop EBV–associated cancers such as Hodgkin’s disease, non-Hodgkin lymphomas, and rare smooth muscle cancers, which reflect chronically increased virus loads due to impaired immune surveillance. EBV can be also associated in the general population with other cancers such as Burkitt’s lymphoma, nasopharyngeal carcinomas, and gastric cancers.

Primary infection with EBV is usually asymptomatic during childhood but can sometimes cause an acute mononucleosis-like illness in adolescents and adults. Subsequently, EBV establishes a lifelong infection where the virus persists in latent form within B cells. It is periodically reactivated to be shed as infectious virus, and its increased replication can also drive lymphoproliferation. Control of both the primary infection and the subsequent EBV reactivation requires robust T and NK cell immunity. This requirement has been demonstrated in conditions characterized by severe immunosuppression such as following HSCT or in CID that have defective lymphocyte functions and broad susceptibility to different viruses and other microbes. Illustrative PIDs in this category include deficiencies in RAS guanyl releasing protein 1 (RASGRP1), CTP synthase 1, Wiskott-Aldrich syndrome protein (WASP), serine/threonine kinase 4 (STK4), DOCK8, coronin 1A, IL-21R, GATA-binding factor 2 (GATA2), and activating mutations in phosphatidylinositol 4,5-biphosphate 3-kinase catalytic subunit delta (PIK3CD) or phosphoinositide 3-kinase regulatory subunit 1 (PIK3R1) (113).

By contrast, several other PIDs display a narrower defect with a heightened susceptibility to EBV relative to other viruses. Studies into these latter disorders have revealed mechanisms that are particularly important for immunity against EBV [reviewed in (113)]. In this category of PIDs are the X-linked lymphoproliferative diseases, caused by hemizygous LOF mutations in *SH2D1A* encoding the signaling adaptor SLAM-associated protein or in *XIAP* encoding the X-linked inhibitor of apoptosis protein. These, or several other mutations that impair cytokotic function because of deficiency in perforin or molecules involved in lytic granule exocytosis, result in prolonged immune activation that, however, is ineffective in suppressing EBV replication and/or can impair cell-cell interaction between EBV-infected B cells and cognate cytotoxic T lymphocytes. When initially infected with EBV, such patients typically present with hemophagocytic lymphohistiocytosis, characterized by life-threatening fulminant lymphoproliferation, macrophage activation, and end-organ damage.

Last, among PIDs that display a relatively selective susceptibility to EBV are those that impair proximal signaling molecules for T cell activation. Such PIDs include deficiencies in IL-2 inducible T cell kinase (ITK), magnesium transporter 1 (MAGT1), CD70, CD27, and CD137 (4-1BB) (113). MAGT1 promotes T cell activation through magnesium second messenger signaling for calcium-dependent responses through its effects on ITK, and ITK activity is directly regulated by Mg2+ (114). In addition, MAGT1 promotes NK cell cytotoxicity against EBV-infected cells through its ability to up-regulate NKG2D on NK and CD8 T cells. Recent studies have identified that MAGT1 participates in an N-glycosylation complex, which is necessary for maturation of fully functional glycosylated NKG2D and CD70 (115, 116). CD70 is normally highly expressed on EBV-infected B cells, and this ligand engages the CD27 costimulatory molecule on T cells. Deficiency in either CD70 or CD27 impairs priming and expansion of EBV–specific CD8 T cells, as well as expression of NKG2D and other molecules important for such cells to interact with and respond to EBV-infected cells. The recent discovery of CD137–deficient patients with poor EBV control indicates that other costimulatory pathways...
can also contribute to anti-EBV immunity (117). Thus, the EBV susceptibility in this category of PIDs may reflect defects in multiple overlapping pathways.

**Phenotypic and genetic heterogeneity of IEI: Converging pathways and allelic heterogeneity**

**Inborn errors of innate-adaptive immunity: Mendelian susceptibility to mycobacterial disease and CMC**

Inborn errors that selectively prevent the development of neutrophils are probably the only pure disorders of innate immunity, echoing the selective disorders of development of T and/or B cells that are pure disorders of adaptive immunity. Only a few inborn errors (such as reticular dysgenesis and telomeropathies) disrupt the development of both innate and adaptive cell types. Most other IEI affect leukocyte function and typically affect both innate and adaptive leukocytes. Two good examples are the inborn errors of IFN-γ and IL-17A/F immunity (118). These are the prototypic type 1 and type 17 signature cytokines and can be secreted by both innate and adaptive leukocytes. In particular, IFN-γ can be secreted by γδ+ γδ+ T cells, and among γδ+ T cells by natural killer T (NKT), mucosa-associated invariant T (MAIT) cells, and conventional CD4+ and CD8+ T cells. It is produced by memory CD4+ T cells, in particular by the T11 and T11* subsets. However, IFN-γ is also produced by B cells, NK cells, and some innate lymphoid cells (ILCs) (119). It serves as the macrophage-activating factor, more so than an antiviral IFN. Patients with any of the 31 known inborn errors of IFN-γ affecting 16 distinct genes are prone to mycobacterial disease and more rarely to related infections by intramacrophagic microbes (120).

These inborn errors were discovered by forward genetics from the study of Mendelian susceptibility to mycobacterial disease (MSMD), a “Mendelian infection” characterized by severe disease caused by poorly virulent mycobacteria, e.g., Bacille Calmette-Guérin vaccines and environmental mycobacteria, in otherwise healthy individuals (118). There is genetic heterogeneity but physiological homogeneity, because all gene products are involved in IFN-γ immunity (Fig. 3).

[Image 38x103 to 132x289]

Interestingly, three IFN-γ–inducing monokines are each essential for optimal production of IFN-γ, because AR IL-12R, IL-23R, and ISG15 deficiencies are all genetic etiologies of MSMD, albeit with incomplete penetrance, which is higher in patients unresponsive to both IL-12 and IL-23 (110, 118, 121). It is interesting that etiologies with low penetrance for MSMD led to the discovery of genetic etiologies of bona fide tuberculosis (122, 123). Whereas the defects that impair responses to IFN-γ are most likely disorders of mononuclear phagocytes, in which mycobacteria reside, the cellular basis of inborn errors of IFN-γ production has proven much more difficult to decipher. A lack of NK, NKT, or B cells alone is not sufficient to be prone to mycobacterial disease, unlike a lack of all T cells. Patients with RORC deficiency have absent (NKT and MAIT) or defective (γδ+ T11*) IFN-γ–producing cells (124). The discovery of additional genetic etiologies of MSMD is required to better delineate the cellular basis of antmycobacterial IFN-γ immunity in humans.

Whereas IFN-γ is the classic TH1 signature cytokine, IL-17A/F is the prototypic TH17 signature cytokine. The role of human IL-17 cytokines in host defense was first suspected when it was shown that patients with APS1, whose only infectious disease is CMC, have neutralizing autoantibodies against IL-17A and IL-17F (53, 54). Patients with inborn errors of IL-17 immunity were discovered from the forward genetic study of isolated and familial forms of CMC (125). The study of patients harboring mutations in IL17RA and IL17A/F genes showed that IL-17 is required for mucocutaneous immunity to *Candida albicans* while being redundant for host defense against other microbes, with the exception of *Staphylococcus aureus*, which can also cause peripheral lesions in the patients. Interestingly, GOF mutations in STAT1 underlie CMC by impairing the production of IL-17A/F- by CD4+ cells, and perhaps by other lymphocytes, probably because of enhanced responses to IFN-γ-producing T cells (126).

IL-17A and IL-17F multimerize to signal via IL-17RA and IL-17RC. Interestingly, patients with IL-17RC deficiency are prone to CMC but not staphylococcal disease, perhaps because responses to IL-25 (IL-17E) are maintained (127). Mutations downstream of the IL-17RA/RC receptor include ACTI deficiency and JNK1 haploinsufficiency (128). The latter defect also impairs the homeostasis of connective tissues, probably in part by disrupting cellular responses to transforming growth factor-β. The nature of the cells that are responsible for the CMC phenotype in patients with inborn errors of the IL-17–responsive pathway remains unclear because IL-17A/F can activate a variety of conjunctive and epithelial cells in the skin and mucosa, promoting their secretion of chemoattractants for leukocytes and also inducing the production of effector genes against fungi. As a matter of fact, the nature of the IL-17–producing lymphocytes that are required for mucocutaneous immunity to *Candida* is also elusive because IL-17A/F can be secreted by γδ+ γδ+ and γδ+ T cells, including at least the T11 and T11* subsets, as well as innate lymphocytes. The discovery of additional genetic etiologies of isolated or syndromic CMC will shed light onto the cellular basis of human CMC, including the roles of IL-17–producing lymphocyte subsets and that of IL-17–responding cells other than leukocytes.

**Inborn errors of nonhematopoietic cell-intrinsic immunity:**

**From epidermodysplasia verruciformis to herpes simplex virus 1 encephalitis**

The study of IEI has also revealed the importance of nonhematopoietic cell-intrinsic immunity for host defense (13). The importance of cells other than leukocytes was already established from the study of thymic
disorders, which were shown from DiGeorge onward to be stromal phenocopies of T cell–intrinsic severe combined immunodeficiency (129). The discovery of the importance of nonhematopoietic cell–intrinsic immunity to viruses came from the study of patients with monogenic infections, whether Mendelian or not. Epidermodysplasia verruciformis (EV) was with hindsight the first described inborn error of immunity in 1946 (130). It is precisely the lack of leukocytic phenotype that prevented its inclusion in the international list of inborn errors of immunity until 2004. These patients are prone to flat warts and pityriasis-like skin lesions that evolve into nonmalignant skin cancer. The lesions are caused by defective β-HPVs, which lack the E5 and E8 virulence genes present in other, more pathogenic HPVs. HPV has an exclusive tropism for keratinocytes. Infection by β-HPV is common and asymptomatic, except in patients with EV.

Typical or isolated EV is defined by a lack of other infections (which are seen in patients with T cell deficits underlying atypical or syndromic EV) (131). The first two genetic etiologies were discovered in 2002, with mutations in TMC6 and TMC8, encoding for EVER1 and EVER2, respectively (132). A third genetic etiology was found more recently, with mutations in CIB1 (133). The three proteins form a complex; in the absence of EVER1 or EVER2, the expression of calcium and integrin binding 1 (CIB1) is dramatically reduced in keratinocytes. Moreover, this complex interacts with E5 and E8, suggesting that it behaves like a human restriction factor for HPVs. A plausible model is therefore that keratinocytes lacking EVER1, EVER2, or CIB1 become permissive to β-HPVs that lack the corresponding virulence factor E5 and E8 and cannot cause lesions in humans with a functional EVER-CIB1 complex. It has proven challenging to test this model experimentally, because it has not yet been possible to establish an in vitro model of the full HPV cycle across all layers of skin keratinocytes.

Another condition that also revealed the importance of cell–intrinsic immunity to viruses by resident, nonhematopoietic cells in specific tissues or organs is a herpes simplex virus 1 (HSV-1) encephalitis (HSE) (134). In the course of primary infection by HSV-1, children rarely prevent the virus from reaching the forebrain via the olfactory bulb or the brainstem via the trigeminal nerves. Until the advent of acyclovir, HSE was almost invariably lethal, and survivors continue to suffer from severe neurological sequelae. Despite its severity, HSE is restricted to the CNS: There are no lesions elsewhere, and the virus cannot even be found in the bloodstream. A forward genetic approach of forebrain HSE found germline mutations in various components of the TLR3 signaling pathway (135). More recently, mutations that do not affect the TLR3-responsive pathway were also found in the SNORA31 gene, encoding a small nuclear RNA (136). Last, mutations in the only known RNA debranched enzyme DBR1 were found in patients with brainstem infection caused by HSV-1, influenza virus, or norovirus (137). Different anatomical territories of the CNS therefore seem to rely on different mechanisms of host defense against viruses.

Leukocytes from patients with inborn errors of the TLR3 pathway do not display any detectable phenotype. In contrast, their fibroblasts and induced pluripotent stem cell (iPSC)–derived cortical neurons and oligodendrocytes show impaired immunity to HSV-1, which can be rescued by exogenous type I IFN (138). Consistent with this, the occurrence of HSE has also been reported in a patient with AR STAT1 deficiency, a condition that impairs cellular response to type I IFN. iPSC-derived trigeminal neurons lacking TLR3 are not more vulnerable than control cells, further suggesting that the cellular basis of disease involves an impairment of CNS-resident cortical neurons (139). The mechanisms by which SNORA31 haploinsufficiency impairs cortical neuron immunity remain to be deciphered. Likewise, neither brainstem neurons (nor any other CNS-resident cell) from DBR1-deficient patients have been tested. Yet, their dermal fibroblasts showed enhanced RNA lariat accumulation and impaired cell–intrinsic immunity to the viruses tested, including HSV-1. The patients’ fibroblasts have only 1 to 3% residual activity, accounting for the massive accumulation of RNA lariats. The mechanism by which these lariats disrupt cell–intrinsic immunity is a topic of intensive study. Overall, the study of HSE and other types of viral encephalitis has revealed the essential role of human CNS-resident, nonhematopoietic cell–intrinsic immunity to viruses.

**Advances in treatment (from supportive care to precision medicine)**

The study of the cellular and molecular IEI has led to major contributions in the treatment of human diseases (Fig. 4). Upon characterization of the cellular phenotype of SCID, and shortly after the initial description of HLA in 1967 (140), allogeneic HSCT was successfully used for the first time in a baby with XR-SCID in 1968 (14). Initially, results were only successful when there was an HLA-identical sibling, because otherwise fatal graft-versus-host disease would develop. Development of methods that allow T cell depletion from the bone marrow enabled the first successful application of an HLA-mismatched HSCT in a patient with SCID in 1983 (141), paving the way for the application of HSCT to a large number of severe hematological and metabolic disorders. Use of chemotherapy or irradiation is typically used to deplete the recipient’s hematopoietic stem and progenitor cells but carries significant risks of toxicity. As an alternative approach to conditioning, injection of anti-CD117 monoclonal antibody targeting hematopoietic stem cells (142) has recently been started (NCT02963064). Last, some forms of severe TCL are of extrahematopoietic origin. Identification of the thymic nature of the immune deficiency has permitted development of thymic transplantation for complete DiGeorge syndrome and other congenital thymic defects (143).

Moreover, identification of the molecular bases of IEI has allowed development of targeted therapeutic approaches based on replacement of the missing product, targeted pharmacological manipulation of the signaling pathway involved, or correction of the gene defect. In 1987, Hershfield reported that enzyme replacement treatment (ERT) with polyethylene glycol–conjugated bovine ADA led to metabolic and immunological improvement in patients with ADA-SCID (144). In 1990, ADA-SCID became the first genetically determined metabolic condition for which ERT was approved by the Food and Drug Administration.

Inborn errors of immune regulation have emerged as an important group of disorders in which newer therapeutic agents are being tested, often with promising initial results (see also Table 1). One example is the use of JAK inhibitors (jakinibs) to treat disease due to heterozygous GOF mutations in STAT1 or STAT3. These diseases cause combinations of infection susceptibility, autoimmunity, inappropriate inflammatory responses, and lymphoproliferation, which have been historically difficult to treat. STAT1 and STAT3 are transcription factors that normally become activated upon stimulation of various cytokine receptors, with IFN receptors activating STAT1 and IL-6, γc, IL-10, or IL-23 receptors activating STAT3. Because GOF mutations confer augmented activity upon cytokine receptor stimulation, which can exert complex downstream effects
on immunity, disease should be amenable to inhibition of JAK adaptors that couple cytokine receptor activation to STAT activation. Efficacy of JAK inhibition in treating both patients with STAT1 and STAT3 GOF has been recently demonstrated (145).

A second example where knowledge of the molecular etiology of PIDs has led to targeted therapies in immunodysregulatory disorders is CTLA-4 haploinsufficiency. Whereas treatment with mTOR inhibitors in these patients can inhibit the increased costimulatory signals, CTLA-4–Fc fusion proteins such as abatacept can alternatively replace the missing CTLA-4 function (146). This new modality seems to be helpful in cases of refractory disease, and a clinical trial is planned for formal testing (NCT03733067). In addition, CTLA-4–Fc fusion proteins may be useful in LRBA and DEF6 deficiencies that phenocopy CTLA-4 haploinsufficiency by increasing CTLA-4 degradation within lysosomes (84).

A third example is the use of small-molecule inhibitors of phosphatidylinositol 3-kinase (PI3K) in activated PI3Kδ syndrome (APDS), a condition characterized by lymphoproliferation and immunodeficiency, with hypogammaglobulinemia with elevated serum IgM, accumulation of senescent T cells, and increased proportion of transitional B cells. In this disease, treatment with leniolisib, a selective PI3Kδ inhibitor, was recently shown in a 12-week open-label dose-escalation safety/efficacy trial to suppress the hyperactive PI3Kδ pathway in patients, normalize abnormal immune biomarkers, and improve lymphoproliferation and autoimmune cytopenias (147). A randomized placebo-controlled study is currently in progress to validate these exciting findings (NCT02435173).

A final example of a disease where extrinsic targeted therapy is being tested is CD55 deficiency with early-onset protein-losing enteropathy and thrombosis. Loss of CD55 results in complement overactivation that is critical for disease pathogenesis, which is supported by anecdotal observations of improved disease upon treatment with the terminal complement inhibitor eculizumab (148). A randomized double-blind, placebo-controlled study is currently in progress to test the efficacy of a pozelimab, a fully human inhibitor of C5 (NCT04209634).

Fig. 4. Progress in the treatment of inborn errors of immunity. Three separate timelines display milestone events in the evolution of cell therapy, gene therapy, and pharmacological treatment to address inborn errors of immunity. FDA, Food and Drug Administration.
Ultimately, correction of the gene defect could provide definitive cure to patients with IEI (15). A first indication in this sense was provided by the observation of somatic mutations (reversions) that restore expression and function of the mutant protein in a clonal lineage, as first demonstrated in 1996 by Hirschhorn et al. for ADA deficiency (149). When the reversion event occurs in an early lymphoid progenitor, it confers a strong selective advantage to T cell progenitors and may even lead to apparent normalization of the immunological phenotype and clinical improvement, as observed in XR-SCID (150).

In the early 1990s, gene therapy was attempted for patients with ADA-SCID initially using gene-modified autologous T cells (151). In 1992, two patients with ADA-SCID were treated with combined autologous T cells and hematopoietic stem and progenitor cells (HSPCs) carrying two distinct γ-retroviral vectors expressing the wild-type ADA gene. This pioneering trial provided seminal demonstration of the selective advantage of cells with restored function and also showed that whereas gene-modified T cells can be beneficial in the short term, long-term reconstitution is derived from gene-modified HSPCs (152). γ-Retroviral–mediated transfer of wild-type ADA complementary DNA (cDNA) under a constitutive promoter (to ensure persistent transgene expression) led to random but stable integration into the genome. The clinical success and safety of this approach, combined with ERT discontinuation and nonmyeloablative conditioning, were further confirmed in 10 patients (153). In 2016, this ex vivo HSPC gene therapy designed to cure ADA-SCID (Strimvelis, Orchard Therapeutics) was approved by the European Medicines Agency, becoming the first gene therapy product approved for commercialization (154).

A similar therapeutic strategy, based on first-generation γ-retroviral vectors, led to successful and rapid reconstitution of T cell immunity in infants with XR-SCID (155). However, six patients developed T cell acute lymphoblastic anemia due to insertion of the transgene into an oncogene (LMO2 in most cases), resulting in transactivation of the oncogene (156). Similar serious adverse events were also reported after initial attempts to treat WAS by gene therapy (157). This prompted investigators to develop safer vector delivery systems. First, second-generation γ-retroviral vectors were generated that were devoid of the potent transactivating long-term repeats of the viral vector and used a cellular promoter to drive expression of the transgene.

Use of such self-inactivating (SIN) γ-retroviral vectors led to robust T cell reconstitution, without occurrence of leukemic events, in patients with XR-SCID (158). Then, SIN-lentiviruses (SIN-LVs) emerged as the most efficient and safest gene delivery vectors for both T cells and HSPCs. Gene therapy with SIN-LV vectors has now been used for numerous monogenic IEIs, including ADA-SCID, XR-SCID, WAS, CGD, and leukocyte adhesion deficiency (LAD) [reviewed in (15)]. Furthermore, addition of reduced-toxicity conditioning regimens has allowed more robust engraftment of gene-corrected HSCs and multilineage immune reconstitution, overcoming the lack of B cell and NK cell reconstitution that has been observed after gene therapy for XR-SCID, when no chemotherapy had been used (159, 160).

However, addition of wild-type copies of the relevant cDNAs would not cure disorders due to GOF and possibly dominant-negative mutations. Furthermore, use of constitutive cellular promoters driving the expression of the transgene could be deleterious in the treatment of disease due to mutations of genes whose expression is tightly regulated, such as CD40LG and FOXP3. In this regard, a recent major advancement in the curative potential of gene therapy has been the development of “gene editing.” Here, a single-nucleotide variant is replaced, or the entire gene coding sequence is inserted precisely at the endogenous locus, using a nuclelease-mediated DNA break and subsequent repair by homologous recombination (161). Gene correction by editing preserves spatiotemporal-regulated gene expression, which is important for genes that are differentially expressed during development and lineage differentiation or that are only expressed upon cell activation. In addition, gene editing is particularly attractive for the correction of dominant-negative mutations. The use of different nucleases has been explored, with the CRISPR-Cas9 nuclease system combined with adeno-associated virus–mediated delivery of the donor template, demonstrating the clearest translational

### Table 1. Targeted therapies for treatment of selected monogenic immune dysregulatory conditions.

<table>
<thead>
<tr>
<th>Immune dysregulatory condition</th>
<th>Molecular pathogenic pathway targeted</th>
<th>Treatment</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>STAT1 GOF</td>
<td>STAT1 hyperactivation</td>
<td>JAK inhibition (ruxolitinib)</td>
<td>(145)</td>
</tr>
<tr>
<td>STAT3 GOF</td>
<td>STAT3 hyperactivation</td>
<td>JAK inhibition (ruxolitinib, tofacitinib)</td>
<td>(145)</td>
</tr>
<tr>
<td>CANDLE syndrome (proteasome complex component LOF)</td>
<td>Type I IFN hyperactivation</td>
<td>JAK inhibition (baricitinib)</td>
<td>(93)</td>
</tr>
<tr>
<td>SAVI (STING GOF)</td>
<td>Type I IFN hyperactivation</td>
<td>JAK inhibition (baricitinib)</td>
<td>(93)</td>
</tr>
<tr>
<td>CTLA-4 haploinsufficiency</td>
<td>T cell costimulatory pathway hyperactivation</td>
<td>CTLA-4–Fc fusion protein (abatacept, belatacept)</td>
<td>(146)</td>
</tr>
<tr>
<td>LRBA deficiency</td>
<td>Increased CTLA-4 degradation leading to T cell costimulatory pathway hyperactivation</td>
<td>CTLA-4–Fc fusion protein (abatacept)</td>
<td>(84)</td>
</tr>
<tr>
<td>APDS (PASLI) (PIK3CD or PIK3R1 GOF)</td>
<td>PI3K pathway hyperactivation</td>
<td>PI3K inhibition (leniolisib)</td>
<td>(147)</td>
</tr>
<tr>
<td>CHAPLE (CD55 deficiency)</td>
<td>Complement hyperactivation</td>
<td>Eculizumab, pozelimab (in testing)</td>
<td>(148)</td>
</tr>
<tr>
<td>Inflammomopathies (NLRP1, NLRP3, PSTPIP1 GOF, LPIN2, MEVK, WDR1, DIRA, or IL-1RN deficiencies, etc.)</td>
<td>IL-1 hyperactivation</td>
<td>IL-1 antagonists (anakinra, canakinumab, rilonacept)</td>
<td>(91)</td>
</tr>
</tbody>
</table>
evidence. Although already in the clinic for the treatment of genetic blood disorders, CRISPR-Cas9 gene editing is still in preclinical phase for correction of IEI. However, feasibility and efficacy have been demonstrated both in vitro and in vivo in mice and in humanized mice models for XR-SCID (162), X-linked hyper-IgM (163), and IPEX (164). Collectively, this work confirms that IEI offer an ideal model system for the exploration and advancement of innovative curative approaches and supports the view that development of gene editing may lead to dramatic improvement in the life of affected patients. Yet, affordability of gene therapy remains a major financial and ethical challenge (165).

CONCLUSIONS
The past 10 years have witnessed gigantic progress in the field of IEI. The number of disorders being discovered is literally growing exponentially, including not only rare but also common genetic defects. The range of clinical phenotypes attributed to IEI is also diversifying at full speed, with an unsuspected diversity of infectious, malignant, autoimmune, autoinflammatory, and allergic phenotypes being caused by monogenic lesions. There is every reason to believe that we have only seen the tip of the iceberg and that countless more IEI will be discovered. Vast areas of medicine, refractory to large population-based association studies, are becoming slowly but surely transformed by the family- and patient-based search for new types of IEI. The next 10 years may very well see conditions as diverse as life-threatening coronavirus disease 2019 (COVID-19) and systemic lupus erythematosus, each deciphered into a myriad of IEI.

REFERENCES AND NOTES


11 of 16
C. P1104A underlies tuberculosis in


**Funding:** L.D.N. and H.C.S. are supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, J.-L.C. is supported by NIH (R01 AI088364, R01 AI107238, R37 AI095983, R01 AI161093, R01 AI127564, and R01 AI136810), National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), “Investments for the Future” program of the French National Research Agency (ANR) (ANR-10-IAHU-01), Laboratoire d'Excellence Integrative Biology of Infectious and Inflammatory Diseases (INSMI), and the Stanford SPARK program. *Author contributions:* All authors equally contributed to the writing of the manuscript. *Competing interests:* The authors declare that they have no competing interests.

Submitted 11 April 2020
Accepted 18 June 2020
Published 10 July 2020
10.1126/sciimmunol.abb1662

Human inborn errors of immunity: An expanding universe
Luigi D. Notarangelo, Rosa Bacchetta, Jean-Laurent Casanova and Helen C. Su

DOI: 10.1126/sciimmunol.abb1662

This article cites 164 articles, 51 of which you can access for free
http://immunology.sciencemag.org/content/5/49/eabb1662#BIBL